Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3759394 | 0.87 | ALDH1A1 (0.34) | ALDH1A1CYP2C9CYP2C19CYP3A4NPSR1 | |
| SCHEMBL3759493 | 0.86 | ALDH1A1 (0.34) | ALDH1A1CYP2C9CYP2C19CYP3A4NPSR1 | |
| SCHEMBL3758518 | 0.85 | ALDH1A1 (0.32) | ALDH1A1CYP2C9CYP2C19CYP3A4NPSR1 | |
| SCHEMBL3751493 | 0.85 | SMN1; SMN2 (0.37) | ALDH1A1CYP2C9CYP2C19CYP3A4NPSR1 | |
| SCHEMBL3759516 | 0.80 | — | — | |
| SCHEMBL4554514 | 0.79 | TSHR (0.35) | ALDH1A1CYP2C9CYP2C19CYP3A4NPSR1 | |
| SCHEMBL3757052 | 0.77 | LMNA (0.39) | ALDH1A1CYP2C9CYP2C19CYP3A4NPSR1 | |
| SCHEMBL3746513 | 0.77 | MEN1 (0.32) | CYP2C9CYP2C19CYP1A2MEN1KMT2A | |
| SCHEMBL4570114 | 0.73 | ALDH1A1 (0.33) | ALDH1A1CYP2C9CYP2C19CYP3A4NPSR1 | |
| SCHEMBL1222406 | 0.73 | MAPT (0.31) | ALDH1A1GAAMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298141-A1 | SUBSTITUTED PYRIDINE N-OXIDE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-25 | — | — | US | claimed |
| US-20100298141-A1 | SUBSTITUTED PYRIDINE N-OXIDE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2120939-A2 | SUBSTITUTED PYRIDINE N-OXIDE HERBICIDES | E. I. Du Pont de Nemours and Company (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008100426-A2 | SUBSTITUTED PYRIDINE N-OXIDE HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298141-A1 | SUBSTITUTED PYRIDINE N-OXIDE HERBICIDES | CYP3A7, CYP2W1, CBR3 | ALDH1A1 434/4885CYP2C9 98/4885CYP2C19 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.